Use of topical bevacizumab for XXXX .

@entity1 @entity5 @entity189 @entity5436 @entity44237
PURPOSE: To report our experience in the treatment of @entity5436 of the conjunctiva using topical bevacizumab. METHODS: Ten eyes of 10 @entity1 with conjunctival @entity5 received 25 mg/mL bevacizumab topically. Changes in the lesions were documented weekly using digital photography. After topical treatment, excisional biopsy was performed. RESULTS: The mean age of the @entity1 was 60.5    12 (33-77) years. The mean duration of topical treatment was 7.8    1.3 (5-14) weeks. The size and vascularity of the @entity5 reduced weekly. All @entity1 underwent excisional biopsy, cryotherapy, and amnion membrane transplantation. The histopathologic diagnosis of the lesions was @entity189 in situ. No recurrence was observed during the follow-up of @entity1 for 6 months. CONCLUSIONS: Topical bevacizumab is an effective treatment to reduce the @entity5 size before surgery and may be a good alternative for adjuvant therapy of @entity44237 .
